

IN THE CLAIMS

Please amend the claims as follows:

1. (Currently amended) A pharmaceutical association composition characterized by ~~being based in~~ either tinidazole or ~~seenidazole~~ and flucozanol and/or an estereoisomer or an acceptable estereoisomeric mixture thereof, ~~in a relationship of comprising from about 400 50 to less than 150 mg fluconazole and from about 1000 to less than 2000 tinidazole, or seenidazole, for the preparation of a medication for the treatment of infectious diseases in the female reproductive system.~~

2. (Currently amended) A pharmaceutical composition characterized by ~~being based on a tinidazole secnidazole and fluconazole and/or an estereoisomer or an estereoisomeric mixture of the same, in a relationship comprising from about 50 to less than 150 mg of fluconazole and 1000 mg to less than 2000 mg of secnidazole, tinidazole, for the preparation of a medication in the treatment of infectious diseases in the female reproductive system.~~

3. (Currently amended) The pharmaceutical composition according to claim 2, characterized by ~~the relationship of the pharmaceutical association is of 75% + 20% in weight of fluconazole and 6% + 20% of secnidazole, tinidazole and the rest of pharmaceutically acceptable vehicles.~~

4. (Currently amended) The composition according to claim 3, characterized in addition because it can be dosified in a pharmaceutical manner for by oral administration.

5. (Currently amended) The pharmaceutical composition according to claim 3, characterized by ~~a the fact that the composition is administered in tablet form.~~

6. (Currently amended) The pharmaceutical composition according to claim 2, characterized ~~in addition by the fact that the~~ ~~by~~ a vehicle mixture of acceptable pharmaceutical vehicles that comprises microcrystalline cellulose, sodium glycolate of starch, polyvinylpyrrolidone, magnesium stearate and white opadry.

7. (Withdrawn) A method for the treatment of infectious diseases in the female reproductive system, comprising ~~in~~ giving a patient suffering such a disease a ~~one~~ single dose ~~in~~ per ~~one~~ day of the pharmaceutical composition ~~mentioned in of~~ Claim 2.

8. (Withdrawn) A method for the treatment of infectious diseases ~~in accordance to with the pharmaceutical composition of~~ claim 7, characterized because wherein the mixed infections infectious disease have has been caused by *Gardnerella Vaginalis, Astinomyces, Candida, Micrococcus, yeast, Proteus, Micrococcus, E. Coli, Trichomonas Vaginilis and or Trichomonas V.* ~~micro-organisms present in vaginitis and vaginosis.~~

9. (Withdrawn) The method according to claim 8, characterized by providing the pharmaceutical composition ~~the fact that the composition is provided in a~~ one tablet form.

10. (Withdrawn) The method according to claim 7 characterized by the fact that ~~it the pharmaceutical composition~~ is administered in a ~~one~~ single dose ~~and~~ containing approximately 112.5 mg of fluconazole and approximately 1.5 g of tinidazole.

11. (Withdrawn) The use of an association of the pharmaceutical compounds of claim 1 which contains fluconazole and tinidazole, wherein the active ingredients are to be found in a relationship from 100 to less than 150 mg of fluconazole and from 1000 to less than 2000 mg of tinidazole for the preparation of to prepare a medication useful in the treatment of infectious diseases in the female reproductive system.

12. (Withdrawn) The use according to claim 11, characterized by comprising wherein the pharmaceutical compound comprises 112.5 mg of fluconazole and 1.5 g of tinidazole.